Novel bronchodilators in asthma

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 1, 2010, Pages 6-12

  Cazzola, Mario ^a   Segreti, Andrea ^a   Matera, Maria G ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Inhaled corticosteroids; Long acting antimuscarinic agents; Once daily combinations of ultra long acting 2 agonists; Ultra long acting 2 agonists

Indexed keywords

ACLIDINIUM BROMIDE; BEA 2180 BR; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BI 1744 CL; BRONCHODILATING AGENT; CARMOTEROL; CHF 5407; CORTICOSTEROID; DAROTROPIUM BROMIDE; DEXPIRRONIUM; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; GSK 573719; GW 642444; INDACATEROL; LAS 100977; LAS 35201; LONG ACTING DRUG; MFF 258; MILVETEROL; MOMETASONE FUROATE; MUSCARINIC RECEPTOR BLOCKING AGENT; PF 3635659; PF 3715455; PF 610355; QAE 397; QAT 370; QMF 149; SALBUTAMOL; SALMETEROL; TD 4208; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; DISEASE CONTROL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EVENING DOSAGE; HUMAN; LUNG FUNCTION; MORNING DOSAGE; NEBULIZATION; NEBULIZER; NONHUMAN; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; QT INTERVAL; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SMOOTH MUSCLE RELAXATION; TACHYCARDIA; TRACHEA MUSCLE; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUSCARINIC ANTAGONISTS; TREATMENT OUTCOME;

EID: 74549205492     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32833303d2     Document Type: Review

References (51)

1. National Asthma Education Prevention Program. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007; 120 (5 Suppl):S94-S138.
2. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-178.
3. Sears MR, Lötvall J. Past, present and future: b2-adrenoceptor agonists in asthma management. Respir Med 2005; 99:152-170.
4. Martinez FD. Safety of long-acting b-agonists: an urgent need to clear the air. N Engl J Med 2005; 353:2637-2639.
5. Walters EH, Gibson PG, Lasserson TJ, Walters JA Long-acting b2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007: CD001385.
6. Magnussen H, Bugnas B, van Noord J, et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med 2008; 102:50-56.
7. Cazzola M, MateraMG, Lötvall J. Ultra long-acting b2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14:775-783.
8. Matera MG, Cazzola M. Ultra-long-acting b2-adrenoceptor agonists. An emerging therapeutic option for asthma and COPD? Drugs 2007; 67:503-515.
9. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008; 155:291-299.
10. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009; 34:757-769.
11. Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. RespirMed 2007; 101:1895-1902.
12. Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 1999; 58 (Suppl 4): 25-33.
13. Kikkawa H, Naito K, Ikezawa K. Tracheal relaxing effects and b2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea-pig tissues. Jpn J Pharmacol 1991; 57:175-185.
14. Voss H-P, Donnell D, Bast A. Atypical molecular pharmacology of a new longacting b2-adrenoceptor agonist, TA-2005. Eur J Pharmacol 1992; 227:403-409.
15. Standifer KM, Pitha J, Baker SP. Carbostyril-based b-adrenergic agonists: evidence for long lasting or apparent irreversible receptor binding and activation of adenylate cyclase activity in vitro. Naunyn Schmiedebergs Arch Pharmacol 1989; 339:129-137.
16. Kikkawa H, Isogaya M, Nagao T, Kurose H. The role of the seventh transmembrane region in high affinity binding of a b2-selective agonist TA-2005. Mol Pharmacol 1998; 53:128-134.
17. Voss HP, Shukrula S, Wu TS, et al. A functional b2 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent b2 adrenoceptor agonist TA 2005. J Pharmacol Exp Ther 1994; 271:386-389.
18. Kikkawa H, Kanno K, Ikezawa K. TA-2005, a novel, long-acting and selective b2-adrenocepter agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other b2-agonists. Biol Pharm Bull 1994; 17:1047-1052.
19. Summerhill S, Stroud T, Nagendra R, et al. A cell-based assay to assess the persistence of action of agonists acting at recombinant human b2 adrenoceptors. Pharmacol Toxicol Methods 2008; 58:189-197.
20. Voss H-P. Long-acting b2-adrenoceptor agonists in asthma: molecular pharmacological aspects [thesis]. Amsterdam: Vrije Universiteit; 1994.
21. Chiesi Farmaceutici S.p.A. Investigator's brochure: CHF 4226. June 2004 (data on file).
22. Haeussermann S, Acerbi A, Brand P, et al. Lung deposition of carmoterol in healthy subjects, patients with asthma and patients with COPD [abstract]. Eur Respir J 2006; 28:211s.
23. Kottakis I, Nandeuil A, Raptis H, et al. Efficacy of the novel very long-acting b2- agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma [abstract]. Eur Respir J 2006; 28:665s.
24. Nandeuil A, Kottakis I, Raptis H, et al. Safety and tolerability of the novel very long acting b2-agonist carmoterol given as a 2mg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma [abstract]. Eur Respir J 2006; 28:665s.
25. Currie GP. Indacaterol Novartis/SkyePharma. Curr Opin Investig Drugs 2006; 7:457-463.
26. Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1- hydroxy-ethyl]-8- hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled b2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317:762-770.
27. Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel longacting b2-agonist, on isolated human bronchi. Eur Respir J 2007; 29:575-581.
28. Sturton RG, Trifilieff A, Nicholson AG, Barnes PJ. Pharmacological characterization of indacaterol, a novel once daily inhaled b2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008; 324:70-75.
29. Battram CH, Mok J, Lewis CA. Once-daily administration of QAB149 does not induce tachyphylaxis in vivo [abstract]. Proc Am Thorac Soc 2005; 2:A356.
30. Tarral A, Fauchoux N, Knight H, et al. Safety and tolerability of multiple-dose indacaterol, a novel b2-agonist, in patients with mild asthma [abstract]. Eur Respir J 2005; 26:253S.
31. Duvauchelle T, Elharrar B, Knight H, et al. Single-dose indacaterol, a novel 24-h b2-agonist, is well tolerated in patients with mild asthma [abstract]. Eur Respir J 2005; 26:253S.
32. Beeh KM, Derom E, Kanniess F, et al. Indacaterol, a novel inhaled b2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007; 29:871-878.
33. Pearlman DS, Greos L, LaForce C, et al. Bronchodilator efficacy of indacaterol, a novel once-daily b2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol 2008; 101:90-95.
34. LaForce C, Korenblat P, Osborne P, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. Curr Med Res Opin 2009; 25:2353-2359.
35. Brookman LJ, Knowles LJ, Barbier M, et al. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr Med Res Opin 2007; 23:3113-3122.
36. Kanniess F, Boulet LP, Pierzchala W, et al. Efficacy and safety of indacaterol, a new 24-h b2-agonist, in patients with asthma: a dose-ranging study. J Asthma 2008; 45:887-892.
37. LaForce C, Alexander M, Deckelmann R, et al. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy 2008; 63:103-111.
38. Chuchalin AG, Tsoi AN, Richter K, et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med 2007; 101:2065-2075.
39. Yang WH, Martinot JB, Pohunek P, et al. Tolerability of indacaterol, a novel once-daily b2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann Allergy Asthma Immunol 2007; 99:555-561.
40. Schnapp A, Bouyssou T, Pestel S, et al. Pharmacological profile of BI 1744 CL, a novel long-acting b2 adrenoceptor agonist [abstract]. Proc Am Thorac Soc 2008; 5:A931.
41. Schnapp A, Pieper MP, Bouyssou T, et al. In vitro characterization of BI 1744 CL, a novel long acting b2 agonist: investigations to understand its long duration of action [abstract]. Am J Respir Crit Care Med 2009; 179:A1919.
42. O'Byrne PM, van der Linde J, Boulet L-P, et al. Single doses of BI 1744 CL, a novel long-acting b2-agonist, are effective for up to 32 hrs in asthmatic patients [abstract]. Proc Am Thorac Soc 2008; 5:A611.
43. Li GL, Mac Intyre F, Surujbally B, et al. Pharmacokinetics of PF-00610355, a novel inhaled long-acting b2-adrenoreceptor agonist [abstract]. Eur Respir J 2009; 34:777s.
44. Macintyre F, Jones I, Surujbally B. A randomised, double-blind study to determine the duration of action of lung pharmacodynamics by plethysmography (sGaw) of a b2 adrenoreceptor agonist, PF-00610355 [abstract]. Eur Respir J 2009; 34:344s.
45. Ward J, Macintyre F, Jones I, et al. A randomised double-blind, study to determine the efficacy & safety of a once-daily inhaled b2 adrenoreceptor agonist, PF-00610355 in asthmatic patients [abstract]. Eur Respir J 2009; 34:778s.
46. Iwamoto H, Yokoyama A, Shiota N, et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J 2008; 31: 1379-1380.
47. Park HW, Yang MS, Park CS, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 2009; 64:778-783.
48. Hansel T, Neighbour H, Erin EM, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilation in patients with asthma. Chest 2005; 128:1974-1979.
49. Rossoni G, Manfredi B, Razzetti R, et al. Positive interaction of the b2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs. Br J Pharmacol 2005; 144: 422-429.
50. Poli G, Devolder A, De Backer W, et al. Pharmacokinetic and pharmacodynamic interaction of carmoterol and budesonide in asthmatic patients [abstract]. Am J Respir Crit Care Med 2009; 179:A2789.
51. Woodcock A, Nandeuil MA, Raptus H, et al. Single dose budesonide/ carmoterol fixed combination improves lung function over 24 h in patients with moderate to severe persistent asthma [abstract]. Eur Respir J 2009; 34:776s.